Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended		99 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012 Since Inception [Member]
Cash Flows From Operating Activities
Net loss	$ (2,594,036)	$ (1,688,640)	$ (90,685,051)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of discontinued operation	0	0	(6,408,603)
Gain on sale of warrants	0	0	(518,622)
Loss on abandonment of leaseholds	0	0	135,344
Depreciation	23,880	26,635	2,027,185
Amortization-intangibles	0	0	2,696,193
Amortization-debt discount	0	0	5,291,019
Amortization-deferred financing costs	0	0	925,859
Amortization-technology and product license fee	33,602	22,727	135,875
Provision for obsolete inventory	0	0	200,000
Change in fair value of warrants	(64,157)	(88,170)	(10,395,709)
Common stock and warrants issued for services and reimbursement of expenses	0	0	203,882
Stock based compensation expense	43,239	22,519	7,471,314
In-process purchased technology	0	0	2,027,529
Changes in operating assets and liabilities
Accounts receivable	(17,546)	0	61,442
Inventories	(87,527)	0	(2,327,816)
Prepaid expenses and other assets	(43,062)	(10,732)	(223,856)
Deposits	0	0	(189,750)
Accounts payable	439,881	(96,208)	2,326,189
Accrued liabilities	36,038	11,063	(182,186)
Deferred rent	(12,960)	(7,591)	105,353
Net cash used in operating activities	(2,242,648)	(1,808,397)	(87,324,409)
Cash Flows From Investing Activities
In-process technology purchased from Tissue Repair Company	0	0	(1,500,000)
Fee paid to list shares issued for technology and product license	0	0	(65,000)
Purchases of property and equipment	0	(1,358)	(2,816,551)
Net cash used in investing activities	0	(1,358)	(4,381,551)
Cash Flows From Financing Activities
Proceeds from officer loan	0	0	62,882
Cash acquired in acquisitions	0	0	1,551,800
Restricted cash - collateral for letter of credit	150,000	100,000	(50,000)
Restricted cash - proceeds placed in escrow from sale of business	0	0	0
Proceeds from the exercise of warrants, net	0	0	1,258,448
Proceeds from debt financing agreement, net of debt issuance costs of $871,833	0	0	14,378,167
Proceeds from the sale of business unit	0	0	11,250,000
Repayment of debt	0	0	(15,750,000)
Proceeds from sales of common stock, net of issuance cost	6,441,891	0	88,075,185
Net cash provided by financing activities	6,591,891	100,000	100,776,482
Net increase (decrease) in cash	4,349,243	(1,709,755)	9,070,522
Cash and cash equivalents at beginning of period	4,721,279	6,644,054	0
Cash and cash equivalents at end of period	9,070,522	4,934,299	9,070,522
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	1,395	1,431	1,390,196
Cash paid for income taxes	0	0	26,162
Non-Cash Activity:
Subscription receivable for common shares	0	0	17,000
Common stock issued for repayment of loans	0	0	62,882
Stock issued for technology license fee	0	0	1,000,000
Net assets acquired for the issuance of common stock (exclusive of cash acquired)	0	0	5,824,000
Warrants exchanged for stock	0	0	(901,139)
Reclassification of derivative liabilities with expired price protection provisions	(21,349)	0	(4,045,702)
Issuance of note for accrued milestone payment	$ 0	$ 0	$ 500,000